Pfizer Berobenatide VESPER-1 Phase 2b at ADA 2026: 15.9% Weight Loss at 32 Weeks With No Plateau, Monthly Dosing Profile
Pfizer presented Phase 2b VESPER-1 data for berobenatide (PF-07976094 / PF'3944), the ultra-long-acting injectable GLP-1 peptide engineered for monthly dosing through a 0.5 mL low-volume injection. At ADA 2026, the 2.4 mg weekly dose drove up to 15.9% mean weight loss at 32 weeks with no plateau across the VESPER program, plus improved glycemic control and favorable tolerability. Pfizer plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies of berobenatide in chronic weight management, knee osteoarthritis, and obstructive sleep apnea. The asset entered Pfizer's pipeline through the $4.9 billion Metsera acquisition.